Compare
Tvardi Therapeutics, Inc. vs Dare Bioscience, Inc. vs Valion Bio, Inc. vs China Pharma Holdings, Inc.
| Latest fiscal year | Tvardi Therapeutics, Inc. TVRD | Dare Bioscience, Inc. DARE | Valion Bio, Inc. VBIO | China Pharma Holdings, Inc. CPHI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.03M | n/a | $4.14M |
| Revenue growth (YoY) | n/a | n/m | n/a | -8.5% |
| Gross margin | n/a | 71.3% (computed) | n/a | -3.2% |
| Operating margin | n/a | n/m | n/a | -78.2% |
| Net margin | n/a | n/m | n/a | -76.9% |
| Net income | -$18.21M | -$13.40M | -$8.88M | -$3.19M |
| EPS (Diluted) | -$3.26 | -$1.20 | n/a | -$0.74 |
| Operating cash flow | -$23.50M | -$9.90M | -$7.00M | $148.3K |
| Free cash flow | n/a | -$10.29M | -$7.04M | $88.9K |
| Cash & equivalents | $20.73M | $24.71M | $12.64M | $345.1K |
| Total assets | $32.07M | $32.47M | $31.61M | $31.00M |
| Total liabilities | $11.13M | $29.63M | $7.44M | $8.26M |
| Shareholders' equity | $20.95M | $2.84M | $16.80M | $22.74M |
| Return on year-end equity | -87.0% | -471.4% | -52.9% | -14.0% |
| Shares outstanding | 9.38M | 14.50M | 2.53M | 15.52M |
Revenue, most recent five fiscal years
| Fiscal year | Tvardi Therapeutics, Inc. | Dare Bioscience, Inc. | Valion Bio, Inc. | China Pharma Holdings, Inc. |
|---|---|---|---|---|
| Latest | $7.14M Ended 2024-12-31 | $1.03M Ended 2025-12-31 | $780.0K Ended 2024-12-31 | $4.14M Ended 2025-12-31 |
| 1 year earlier | $20.97M Ended 2023-12-31 | $9.8K Ended 2024-12-31 | $1.18M Ended 2023-12-31 | $4.53M Ended 2024-12-31 |
| 2 years earlier | $41.87M Ended 2022-12-31 | $2.81M Ended 2023-12-31 | $1.84M Ended 2022-12-31 | $7.01M Ended 2023-12-31 |
| 3 years earlier | $23.03M Ended 2021-12-31 | $10.00M Ended 2022-12-31 | $1.26M Ended 2021-12-31 | $8.10M Ended 2022-12-31 |
| 4 years earlier | $135.08M Ended 2020-12-31 | $0 Ended 2021-12-31 | n/a | $9.64M Ended 2021-12-31 |